Amer Zeidan, Associate Professor of Department of Internal Medicine and Hematology at Yale School of Medicine, shared on X:
“Ask the Expert: COMMANDS Trial Results of First-Line Luspatercept Versus Epoetin Alfa in Transfusion-Dependent Patients With Lower-Risk Myelodysplastic Syndromes – Personalized Medicine in Oncology.”
Read Further.
Source: Amer Zeidan/X